1975至2019年美国甲状腺癌发病率、转移和死亡率的趋势:基于人群的年龄、时期和队列效应研究
该研究利用美国NCI监测、流行病学和最终结果数据库及国家卫生统计中心数据库1975至2019年数据,纳入91968例甲状腺癌患者,采用Joinpoint回归和年龄-时期-队列模型分析趋势。结果显示年发病率从1975年每10万人5.0例升至2009年14.6例后至2019年平台期,变化主要由时期效应驱动,年龄差异似乎主要由过度诊断驱动。
要点
- 甲状腺癌年发病率从1975年每10万人5.0例升至2009年14.6例,后至2019年平台期。
- 年龄-时期-队列分析提示发病率变化主要由时期效应驱动。
- 发病率上升在40-69岁女性和50-79岁男性中最明显,且各出生队列发病率逐代增加。
核心结论
- 美国甲状腺癌发病率上升及随后的平台期主要由时期效应驱动,可能源于诊断压力模式的变化。
- 研究期间发病率随年龄的变化似乎主要由过度诊断驱动。
- 尽管发病率已平台化,但仍处于峰值水平,提示过度诊断仍是未解决的重要公共卫生问题。
- 需要进一步工作以帮助限制当前过度诊断的驱动因素,并实施针对医生、患者和政策制定者的新解决方案。
研究设计与样本
- 回顾性、基于人群的研究,使用美国国家癌症研究所监测、流行病学和最终结果数据库及国家卫生统计中心数据库1975至2019年发病率数据。
- 纳入依据第三版国际肿瘤学疾病分类(部位代码C73.9)且组织学为恶性的甲状腺癌患者。
- 样本共91968例甲状腺癌患者,其中男性23467例(25.5%),女性68501例(74.5%)。
- 使用NCI的Joinpoint回归程序估计发病率随时间趋势,并使用年龄-时期-队列模型识别影响因素。
主要发现
- 甲状腺癌年发病率从1975年每10万人5.0例增至2009年每10万人14.6例,之后至2019年处于平台期。
- 年龄-时期-队列分析提示发病率变化主要由时期效应驱动。
- 发病率上升在40-69岁女性和50-79岁男性中最明显。
- 在所有时间段,女性和男性中发病率均随每个连续出生队列而增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the USA, the incidence of thyroid cancer increased rapidly for several decades, although some studies have suggested that it has now plateaued or even begun to decrease. We aimed to establish whether incidence in the USA has truly decreased or merely plateaued, and to understand some of the underlying factors driving these changes. METHODS: We conducted a retrospective, population-based study using the National Cancer Institute (NCI)'s Surveillance, Epidemiology, and End Results database and the National Center for Health Statistics database. We used incidence data from these registries obtained between 1975 and 2019, including patients with a diagnosis of thyroid cancer according to the third edition ICD for Oncology (site code C73.9) and malignant histology. We used the NCI's Joinpoint Regression Program to estimate trends in the incidence over time and age-period-cohort modelling to identify the factors influencing these trends. FINDINGS: Our sample included 91 968 patients with thyroid cancer, of whom 23 467 (25·5%) were men and 68 501 (74·5%) were women. The annual incidence of thyroid cancer increased from 5·0 cases per 100 000 people in 1975 to 14·6 cases per 100 000 people in 2009, before plateauing until 2019. The age-period-cohort analysis suggests that the changes in incidence were primarily due to time period effects. Furthermore, the increase in incidence was most prominent among women aged 40-69 years and men aged 50-79 years. Throughout all time periods, incidence increased with each successive birth cohort among both women and men. INTERPRETATION: The rise and subsequent plateau in the incidence of thyroid cancer in the USA have been primarily driven by time period effects, likely due to changing patterns in diagnostic pressure. Variations in the incidence of thyroid cancer by age, which increased during the time frame of this study, seem to be driven predominantly by overdiagnosis. Although the incidence of thyroid cancer has plateaued, it remains at peak levels, suggesting that overdiagnosis remains a crucial unresolved public health issue. Further work is needed to help limit the current drivers of overdiagnosis and to implement novel solutions aimed at both physicians, patients, and policy makers. FUNDING: None.
引用
- Chen MM, Luu M, Sacks WL, et al. Trends in incidence, metastasis, and mortality from thyroid cancer in the USA from 1975 to 2019: a population-based study of age, period, and cohort effects. Lancet Diabetes Endocrinol. 2025. PMID: 39922210. doi:10.1016/S2213-8587(24)00310-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。